146 related articles for article (PubMed ID: 1544386)
1. Differential cytotoxicity of an ether lipid on lymphoma and bone marrow cells and its role in purging malignant lymphoid cells from remission bone marrow contaminated with tumor cells.
Dietzfelbinger HF; Lang A; Oberberg D; Rastetter JW; Berdel WE
Exp Hematol; 1992 Feb; 20(2):178-83. PubMed ID: 1544386
[TBL] [Abstract][Full Text] [Related]
2. Removal of breast cancer cells from bone marrow by in vitro purging with ether lipids and cryopreservation.
Dietzfelbinger HF; Kühn D; Zafferani M; Hanauske AR; Rastetter JW; Berdel WE
Cancer Res; 1993 Aug; 53(16):3747-51. PubMed ID: 8339286
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxicity of VP-16-213 and nitrogen mustard: agonistic on tumor cells but not on normal human bone marrow progenitors.
Lemoli RM; Gulati SC
Exp Hematol; 1990 Oct; 18(9):1008-12. PubMed ID: 2397748
[TBL] [Abstract][Full Text] [Related]
4. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
5. Elimination of clonogenic tumor cells from bone marrow using methylprednisolone (MP) and etoposide VP16: an in vitro pharmacologic study.
Miller G; Brashear T; Stone M; Fay J
Int J Cell Cloning; 1991 Sep; 9(5):503-10. PubMed ID: 1955738
[TBL] [Abstract][Full Text] [Related]
6. Photoradiation methods for purging autologous bone marrow grafts.
Gulati S; Atzpodien J; Lemoli RM; Shimazaki C; Clarkson B
Prog Clin Biol Res; 1990; 333():87-102. PubMed ID: 2137934
[TBL] [Abstract][Full Text] [Related]
7. The alkyl-lysophospholipid, ET-18-OCH3 synergistically enhances the Merocyanine 540-mediated photoinactivation of leukemia cells: implications for the extracorporeal purging of autologous hematopoietic stem cells.
Yamazaki T; Sieber F
Bone Marrow Transplant; 1997 Jan; 19(2):113-9. PubMed ID: 9116607
[TBL] [Abstract][Full Text] [Related]
8. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
[TBL] [Abstract][Full Text] [Related]
9. The sensitivity of leukemic bone marrow to simvastatin is lost at remission: a potential purging agent for autologous bone marrow transplantation.
Newman A; Clutterbuck RD; DeLord C; Powles RL; Catovsky D; Millar JL
J Investig Med; 1995 Jun; 43(3):269-74. PubMed ID: 7614073
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxicity of alkyl-lysophospholipid on clonogenic leukemia cells and on normal bone marrow progenitor cells is highly, but differentially, increased by cryopreservation.
Verdonck LF; Heesbeen EC; van Heugten HG; Staal GE; Rijksen G
Bone Marrow Transplant; 1992 Apr; 9(4):241-5. PubMed ID: 1600412
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a combined treatment with ASTA-Z 7654 and VP16-213 in vitro in eradicating clonogenic tumor cells from human bone marrow.
De Fabritiis P; Pulsoni A; Sandrelli A; Simone F; Amadori S; Meloni G; Mandelli F
Bone Marrow Transplant; 1987 Oct; 2(3):287-98. PubMed ID: 3502785
[TBL] [Abstract][Full Text] [Related]
13. Role of cytoprotective mechanisms in the photochemical purging of autologous bone marrow grafts.
Yamazaki T; Sato Y; Sieber F
Exp Hematol; 1997 Jul; 25(7):629-37. PubMed ID: 9216739
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitro.
Danhauser-Riedl S; Himmelmann A; Steinhauser G; Busch R; Vogler WR; Rastetter J; Berdel WE
J Lipid Mediat; 1990; 2(5):271-80. PubMed ID: 2133272
[TBL] [Abstract][Full Text] [Related]
15. Elimination of leukemic cells by the combined use of ether lipids in vitro.
Okamoto S; Olson AC; Vogler WR
Cancer Res; 1987 May; 47(10):2599-603. PubMed ID: 3471316
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
Verma UN; Bagg A; Brown E; Mazumder A
Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
[TBL] [Abstract][Full Text] [Related]
17. Cumulative chemotherapy increases mafosfamide toxicity for normal progenitor cells in AML patients: rationale for cryopreserving adapted-dose purged marrow early in first complete remission.
Martin H; Bruecher J; Claudé R; Hoelzer D
Bone Marrow Transplant; 1993 Nov; 12(5):495-9. PubMed ID: 8298560
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of purging clonogenic leukemia cells using ether lipid and hyperthermia for autologous bone marrow transplantation.
Min WS; Park HM; Han CH; Park JW; Kim CC; Kim DJ
Prog Clin Biol Res; 1992; 377():87-95. PubMed ID: 1438449
[No Abstract] [Full Text] [Related]
19. Etoposide as an in vitro purging agent for the treatment of acute leukemias and lymphomas in conjunction with autologous bone marrow transplantation.
Ciobanu N; Paietta E; Andreeff M; Papenhausen P; Wiernik PH
Exp Hematol; 1986 Aug; 14(7):626-35. PubMed ID: 3525202
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
Charak BS; Malloy B; Agah R; Mazumder A
Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]